{"entity":{"id":"idea-bispecific-vs-car-t-second-line","kind":"idea","name":"Head-to-head bispecific vs CAR-T in second-line LBCL","aka":[],"tldr":"Nobody has directly compared an off-the-shelf bispecific with CAR-T in the same patients; a trial would settle where each belongs.","summary":"The idea is a head-to-head randomised trial of an off-the-shelf CD20 bispecific, epcoritamab or glofitamab with chemotherapy, against the CAR-T product axicabtagene ciloleucel in second-line large B-cell lymphoma. CAR-T has phase 3 event-free and overall survival wins in early relapse, while bispecifics have single-arm data and one mixed phase 3 in EPCORE DLBCL-1, but can be repeated, arrive within a week, and win on access and cost. The hypothesis is that a bispecific with chemotherapy is non-inferior to axi-cel on event-free survival at lower cost with comparable cytokine release syndrome. The test is a randomised non-inferiority trial with quality of life and cost as secondary endpoints; the speculative idea addresses the manufacturing bottleneck.","asOf":"2026-09-07","links":[{"label":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early (New England Journal of Medicine 2022)","url":"https://doi.org/10.1056/NEJMoa2116133"},{"label":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma (New England Journal of Medicine 2017)","url":"https://doi.org/10.1056/NEJMoa1707447"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["t-cell-engager","car-t"],"targets":[],"drugs":["epcoritamab","glofitamab","axicabtagene-ciloleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-1-axi-cel-nejm-2017","paper-glofitamab-dlbcl-n-engl-j-med-2022","paper-glofitamab-dlbcl-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Epcoritamab or glofitamab with chemotherapy is non-inferior to axi-cel on EFS in second-line LBCL with a lower cost and comparable CRS.","rationale":"Both redirect T cells to CD19/CD20+ cells; bispecifics can be repeated and are available in a week.","test":"Randomised non-inferiority trial with EFS primary, quality-of-life and cost secondary; ctDNA-defined stratification.","maturity":"speculative"},"route":"/ideas/idea-bispecific-vs-car-t-second-line/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"}],"paper":[{"id":"paper-glofitamab-dlbcl-n-engl-j-med-2022","kind":"paper","name":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/"},{"id":"paper-glofitamab-dlbcl-lancet-2024","kind":"paper","name":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","route":"/key-papers/paper-glofitamab-dlbcl-lancet-2024/"},{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}]}}